SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

Traders are focused on the Fed's interest rate decision and upcoming comments from Powell, with a rate cut largely priced in. Community chatter revolves around the potential market reaction, the end of quantitative tightening, and the possibility of a 'sell the news' event. Some are also watching for potential impacts from big tech earnings and upcoming meetings between Trump and Chinese leaders.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders react to Fed Chair Powell's comments and anticipate a potential rate cut decision, sparking volatility. Community members are debating whether recent market gains are sustainable amid concerns of an AI bubble and overvalued conditions. Discussions also include the potential impact of Trump's meeting with Xi on trade and tariffs.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

Following earnings, UNH is experiencing volatility as the community debates whether recent price movement is due to manipulation, profit-taking, or reflects genuine concerns about forward guidance and profitability. Bullish investors point to long-term growth prospects and potential catalysts, while others express frustration with the stock's performance compared to its peers. Traders are closely watching for potential support levels and signals for potential swing trades.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending as investors anticipate results from the HOPE-3 trial in November, with discussions focusing on potential data leaks and speculation around positive outcomes. Community members are actively debating the likelihood of approval based on both PUL and LVEF endpoints, while others point to increased volume and recent executive job postings as bullish signals. Some traders are highlighting options activity and potential short squeezes, adding to the stock's current momentum.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to a significant stock drop following disappointing earnings and a lowered outlook, which has sparked debates about a potential short squeeze and whether the sell-off is an overreaction. The community is actively discussing the company's fundamentals, institutional ownership, and potential for a rebound, with some viewing the dip as a buying opportunity and others remaining cautious. Concerns are also emerging around the company's debt and future growth prospects in a changing financial landscape.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the community discusses potential catalysts like the Fed rate decision and the upcoming Trump-Xi meeting, while also reacting to news of large ETH acquisitions by institutions. Despite some bullish sentiment and talk of a potential breakout, concerns about market manipulation and recent price drops are fueling mixed opinions. Community members are closely watching key support levels and debating whether ETH can sustain its upward momentum amidst broader market volatility.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as investors react to mixed signals, including potential Fed rate cuts and ongoing trade tensions. The community is actively discussing whether recent price movements reflect a genuine flight to safety or a temporary reaction. Broader concerns around economic slowdown and the impact of tariffs on inflation are also contributing to the conversation.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing ($BA) is trending due to a mix of positive and negative catalysts, with a focus on Q3 earnings, a $4.9B charge related to 777X delays, and positive free cash flow. Community sentiment is divided as some express concerns about profitability, debt, and ongoing strike actions, while others see potential for recovery and are encouraged by defense contracts and 737 ramp-up. Discussions also include speculation on potential deals with China and the impact of CEO Ortberg's leadership.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid community discussions around market volatility, potential rate cuts, and technical analysis patterns. Michael Saylor's bullish forecast of Bitcoin reaching $150,000 by year-end is fueling optimism, while some traders are closely watching for a potential short squeeze. The conversation also includes the impact of potential government regulations and broader macroeconomic factors.

Stride, Inc. is a technology-based educational company, which engages in the provision of proprietary and third-party curriculum, software systems and educational services. It also offers online curriculum and career services to middle and high school students, under the Destinations Career Academy brand name. The company was founded by Ronald J. Packard in 2000 and is headquartered in Reston, VA.

Stride Inc

Stride's stock is trending due to a significant market overreaction following the company's earnings report and Q2 guidance, with the community debating whether the dip presents a buying opportunity or signals deeper issues. Despite the company beating earnings expectations, concerns about platform upgrades and future growth are fueling the volatility. Community members are closely watching institutional ownership and algorithmic trading patterns to determine the stock's next move.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ACST.DL1224 &#39;42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks&#39;...This blows AMRN out of the water.These people didn&#39;t have the placebo in their systems to see these kinds of results...Stay tuned!

Lawrence Valure

(e)Quanimus Investments

Joey Tokes

Mr. Mysterious

Oveja Bohemia

Stocks Investor

STARlab

StockTwits for iOS

StockTwits Web

Acasti Pharma Inc

$ACST '42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks'...This blows AMRN out of the water.These people didn't have the placebo in their systems to see these kinds of results...Stay tuned!

glen philippe

I should&#39;ve added,we are better when adding the probable Secondary Endpoints...The Primary is basically the same as Vascepa,at 45%...We just used a different placebo to match up against,for whatever reason...If everything else plays out like this,it will only be the placibo that remains the problem and not the drug itself...The FDA will have to address that as possibly being their fault.You have to match both drugs against the same placibo for any trial to matter.Otherwise one drug has a possible advantage over the other,such as this time.

Alex

I should've added,we are better when adding the probable Secondary Endpoints...The Primary is basically the same as Vascepa,at 45%...We just used a different placebo to match up against,for whatever reason...If everything else plays out like this,it will only be the placibo that remains the problem and not the drug itself...The FDA will have to address that as possibly being their fault.You have to match both drugs against the same placibo for any trial to matter.Otherwise one drug has a possible advantage over the other,such as this time.

Imo,the placebo data may get thrown out if this continues in the 2nd arm,and they&#39;ll use the data that Amarin used for their placebo,as the FDA is involved in the planning of the trials.,,The rest of the results are outstanding.

Imo,the placebo data may get thrown out if this continues in the 2nd arm,and they'll use the data that Amarin used for their placebo,as the FDA is involved in the planning of the trials.,,The rest of the results are outstanding.

@robinandthe7hoods what exact data of the reduce it trial are you claiming acst will be able to use as their data? I&#39;m gonna go with 0. Acst cannot use data from another trial for their p3. Capre and vascepa are 2 different drugs...the data does not transfer which is why capre was hoping to use the strength data but that hope is gone now.

Valentin

StockTwits For Android 

 what exact data of the reduce it trial are you claiming acst will be able to use as their data? I'm gonna go with 0. Acst cannot use data from another trial for their p3. Capre and vascepa are 2 different drugs...the data does not transfer which is why capre was hoping to use the strength data but that hope is gone now.

Matt Jones

@robinandthe7hoods You really don&#39;t understand why a placebo is used do you?? The placebo was inert that&#39;s why the effect was only witnessed at 5 out of 54 sites.  You cant claim a  42% reduction for CAPre if those that were not taking it had a 30% improvement. Hence the need for an investigation because if they can&#39;t show  that the placebo group were either not given a placebo or took something other than the placebo then the result as it stands is correct

 You really don't understand why a placebo is used do you?? The placebo was inert that's why the effect was only witnessed at 5 out of 54 sites.  You cant claim a  42% reduction for CAPre if those that were not taking it had a 30% improvement. Hence the need for an investigation because if they can't show  that the placebo group were either not given a placebo or took something other than the placebo then the result as it stands is correct